Abstract
Meeting abstracts Melanoma vaccines have been designed to expand specific CD8+ T-cells, but melanoma-reactive helper T-cells also can have antitumor activity. We previously observed clinical activity of a vaccine incorporating 6 melanoma helper peptides (6MHP), and found associations between CD4+ T
Highlights
Melanoma vaccines have been designed to expand specific CD8+ T-cells, but melanoma-reactive helper T-cells can have antitumor activity
CD4+ T-cell proliferation was assessed by thymidine uptake after exposure to peptides
CD8+ T-cell response was assessed by direct IFN-g ELIspot assay against 14 MHC class I-restricted peptides
Summary
Melanoma vaccines have been designed to expand specific CD8+ T-cells, but melanoma-reactive helper T-cells can have antitumor activity. We previously observed clinical activity of a vaccine incorporating 6 melanoma helper peptides (6MHP), and found associations between CD4+ T cell response and survival. In the spirit of personalized cancer immunotherapy, we define the relative immunogenicity and HLA allele promiscuity of individual helper peptides, and Figure 1. Identify helper peptide-mediated augmentation of melanoma-specific CD8+ T-cell response
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
